Travere Therapeutics, Inc. TVTX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | -$88.54M+74.8% | -$169.06M-15.9% | -$226.71M-40.7% | ||
| $73.15M+57.4% | $60.74M+39.5% | $54.7M+33.6% | $50.15M+21.8% | $46.48M+11.2% | ||
| $49.52M+28.1% | $44.87M+21.6% | $42.62M+18.9% | $39.38M+0.6% | $38.65M-4.7% | ||
| —— | —— | —— | —— | -$160.66M+49.5% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | $78.97M+18,395% | $144.36M+37,789% | $143.67M+7,603% | ||
| —— | —— | $74.52M+169% | $42.86M+211% | $18.65M+116% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Travere Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Travere Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.